Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients

12 Jan 2018

Abstract excerpt

BACKGROUND: Noninvasive biomarkers to guide personalized treatment for castration-resistant prostate cancer (CRPC) are needed. In this study, we analyzed hypermethylation patterns of two genes (GSTP1 and APC) in plasma cell-free DNA (cfDNA) of CRPC patients. The aim of this study was to analyze the cfDNA concentrations and levels of the epigenetic markers and to assess the value of these biomarkers for prognosis....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29330943
DOI: 10.1002/pros.23477

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patientsPMID 29330943Read ↗

DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate CancerSemantic proximity Read ↗

Cell‐free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast CancerSemantic proximity Read ↗

Increased Sensitivity of Detection of RASSF1A and GSTP1 DNA Fragments in Serum of Prostate Cancer Patients: Optimisation of Diagnostics Using OBBPA-ddPCRSemantic proximity Read ↗

The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancerSemantic proximity Read ↗

Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal CancerSemantic proximity Read ↗

Diagnostic Value of GSTP1, RASSF1, AND RASSF2 Methylation in Serum of Prostate Cancer Patients.Semantic proximity Read ↗

Genome-wide plasma DNA methylation features of metastatic prostate cancerSemantic proximity Read ↗

Tumor fraction in cell-free DNA as a biomarker in prostate cancerSemantic proximity Read ↗

Circulating Tumor DNA Biomarkers for Response Assessment in Prostate CancerSemantic proximity Read ↗

Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA MethylationSemantic proximity Read ↗

5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapiesSemantic proximity Read ↗

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.